Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Soc...
September 19 2017 - 3:11PM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced
that data for its drug candidate CB-839, an orally bioavailable
glutaminase inhibitor, will be presented at the 32nd Annual Meeting
of the Society for Immunotherapy of Cancer (SITC), which is being
held from November 10 to November 12, 2017, at the Gaylord National
Hotel & Convention Center in National Harbor, Maryland.
Clinical results to be presented include data from
Calithera’s trial of CB-839 dosed in combination with Opdivo®
(nivolumab) in patients with advanced melanoma, renal cell
carcinoma, or non-small cell lung cancer. The trial is the
subject of a clinical collaboration with Bristol-Myers Squibb.
A phase 1/2 study of CB-839, a first-in-class
glutaminase inhibitor, combined with nivolumab in patients with
advanced melanoma, renal cell carcinoma or non-small cell lung
cancer.Presenter: Dr. Funda Meric-Bernstam, MD
Anderson Cancer CenterSession: Clinical Trials: Novel Combinations
Session Date and Time: November 11, 2017, 3:30 p.m. – 6:00 p.m.
ET
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical
company focused on discovering and developing novel small molecule
drugs directed against tumor metabolism and tumor immunology
targets for the treatment of cancer. Calithera’s lead product
candidate, CB-839, is an inhibitor of glutaminase. CB-839 takes
advantage of the pronounced dependency many cancers have on the
nutrient glutamine for growth and survival. It is currently being
evaluated in Phase 2 clinical trials. CB-1158 is an
investigational immuno-oncology metabolic checkpoint inhibitor
designed to target arginase, a critical immunosuppressive enzyme
responsible for T-cell suppression by myeloid-derived suppressor
cells (MDSCs). Arginase depletes arginine, a nutrient that is
critical for the activation, growth and survival of the body’s
cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158
is being developed in collaboration with Incyte Corporation and is
currently in a Phase I clinical trial. Calithera is headquartered
in South San Francisco, California. For more information about
Calithera, please visit http://www.calithera.com/.
Forward-Looking Statement Statements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
"may," "will," "expect," "anticipate," "estimate," "intend,"
"poised" and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking statements.
These statements include those related to the safety,
tolerability and efficacy of CB-839, Calithera’s plans to continue
development of CB-839 in combination therapy for clear cell renal
cell carcinoma, the potential for combining nivolumab (marketed as
Opdivo) with CB-839 to drive improved and sustained efficacy in
clear cell renal cell carcinoma and other cancers, including NSCLC
and melanoma, and the advancement of CB-839 in clinical
trials. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release.
Such product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations
with respect to any of the foregoing matters may have a negative
effect on Calithera's stock price. Additional information
concerning these and other risk factors affecting Calithera's
business can be found in Calithera's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission,
and other periodic filings with the Securities and Exchange
Commission at www.sec.gov. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, Calithera
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
Contact:
Calithera BiosciencesJennifer McNealey 650-870-1071
ir@Calithera.com
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024